Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effects of Panax ginseng in Neurodegenerative Diseases.
Twin studies and the heritability of MS: a conclusion.
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
[Cognitive impairment in demyelinating disease].
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
Validity and reliability of VO2-max measurements in persons with multiple sclerosis.
Drug record: Amiloride
Current and future drugs for treatment of MS-associated bladder dysfunction.
Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Epidural blood patch in a patient with multiple sclerosis: is it safe?
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
MiR-126: a novel route for natalizumab action?
Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Management of children with multiple sclerosis.
Progressive multiple sclerosis: The treatment gap.

Pages